ClinicalTrials.gov
Cure8 trial brief
Why This Matters
People with ulcerative colitis and their clinicians may find real-world safety and disease-activity data helpful when deciding about upadacitinib (Rinvoq) treatment. Observational registries can reveal how a drug performs across routine clinical settings and patient types not always represented in randomized trials.
Who Should Pay Attention
Adult patients with moderate-to-severe ulcerative colitis, gastroenterologists and IBD clinicians, safety researchers, and others monitoring real-world outcomes of JAK inhibitors
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment308 participants
Study statusCompleted
Source depthTrial registry record
What To Know
This is a real-world, non-interventional study rather than a randomized trial. Participants received upadacitinib as prescribed by their physicians; the registry tracked adverse events and disease-activity measures during usual-care visits.
The study aimed to capture safety signals and how disease activity changed in everyday practice after Rinvoq approval in Japan. The registry included adults (minimum age 15) who began Rinvoq within 14 days of enrollment and excluded prior Rinvoq exposure or concurrent participation in registrational trials.
Follow-up visits aligned with routine clinical practice, and there was no extra study burden planned beyond usual visits.
Keep In Mind
This is an observational registry (completed) — it collects real-world data but does not randomize or control treatments. The ClinicalTrials.gov entry summarizes planned outcomes and design; it is not a peer-reviewed study report. observational data can be affected by selection bias and confounding.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorAbbVie
Trial IDNCT05791526
Study typeObservational
Enrollment308 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedOct 5, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
Real-world registry data on upadacitinib can help patients and clinicians understand how the drug performs outside clinical trials, including patterns of use, effectiveness, and safety over time.
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
This study will collect real-world data on etrasimod, an oral S1P receptor modulator, in people with ulcerative colitis, using patient-reported symptom measures over one year — information that may help patients and...
A Study to Assess Guselkumab in Participants With Moderate-to-Severe Inflammatory Bowel Disease in Real Life Italian Setting
This registry will collect real-world data on guselkumab use in adults with moderate-to-severe Crohn's disease or ulcerative colitis, focusing on how long patients stay on treatment, effectiveness in routine practice,...